psalexa
logo

Acne Vulgaris Therapeutics

Acne Vulgaris Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, Epidemiology Forecast to 2023, and Unmet Needs within the Market

Published: November 2017
Report Code: LS11275
Available Format:
Pages: 157

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

This report includes the acne vulgaris therapeutics pipeline analysis and epidemiology forecast to 2023, to evaluate patient population in the 7MM market and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to acne vulgaris.

Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Epidemiology and Patient Population Forecast to 2023 for 7MM:

  • U.S.
  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Japan

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry